Patents by Inventor Nathaniel D. Catron

Nathaniel D. Catron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20200277291
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: October 24, 2019
    Publication date: September 3, 2020
    Applicant: AbbVie Inc.
    Inventors: Zhi-Fu Tao, Xilu Wang, Andrew J. Souers, Nathaniel D. Catron, Gerard M. Sullivan
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20190315737
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: November 28, 2018
    Publication date: October 17, 2019
    Inventors: Zhi-Fu Tao, Xilu Wang, Andrew J. Souers, Nathaniel D. Catron, Gerard M. Sullivan
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20170096424
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: June 30, 2016
    Publication date: April 6, 2017
    Inventors: Zhi-Fu Tao, Xilu Wang, Andrew J. Souers, Nathaniel D. Catron, Gerard M. Sullivan
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 9403822
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: August 2, 2016
    Assignee: ABBVIE INC.
    Inventors: Zhi-Fu Tao, Xilu Wang, Andrew J Souers, Nathaniel D. Catron, Gerard M. Sullivan
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20150246914
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: March 11, 2015
    Publication date: September 3, 2015
    Inventors: Zhi-Fu Tao, Xilu Wang, Andrew J Souers, Nathaniel D. Catron, Gerard M. Sullivan
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 9006247
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: April 14, 2015
    Assignee: AbbVie Inc.
    Inventors: Zhi-Fu Tao, Xilu Wang, Andrew J. Souers, Nathaniel D. Catron, Gerard M. Sullivan
  • ABT-263 capsule
    Patent number: 8927009
    Abstract: A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: January 6, 2015
    Assignee: AbbVie Inc.
    Inventors: Ping Tong, Deliang Zhou, Geoff G. Z. Zhang, Katherine R. Heemstra, Cristina M. Fischer, Nathaniel D. Catron, Eric A. Schmitt, Yeshwant D. Sanzgiri
  • ABT-263 crystalline forms
    Patent number: 8513243
    Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: August 20, 2013
    Assignee: AbbVie Inc.
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt
  • ABT-263 crystalline forms
    Patent number: 8362014
    Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: January 29, 2013
    Assignee: AbbVie Inc.
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20120028925
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: May 25, 2011
    Publication date: February 2, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Zhi-Fu Tao, Xilu Wang, Andrew J. Souers, Nathaniel D. Catron, Gerard M. Sullivan
  • ABT-263 CRYSTALLINE FORMS
    Publication number: 20110294811
    Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Application
    Filed: July 28, 2011
    Publication date: December 1, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt
  • ABT-263 CAPSULE
    Publication number: 20110159085
    Abstract: A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Application
    Filed: December 21, 2010
    Publication date: June 30, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Ping Tong, Deliang Zhou, Geoff G.Z. Zhang, Katherine R. Heemstra, Cristina M. Fischer, Nathaniel D. Catron, Eric A. Schmitt, Yeshwant D. Sanzgiri
  • ABT-263 CRYSTALLINE FORMS
    Publication number: 20110071151
    Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Application
    Filed: September 15, 2010
    Publication date: March 24, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Geoff G.Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt